Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With Asthma and Allergic Bronchopulmonary Aspergillosis

X
Trial Profile

Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With Asthma and Allergic Bronchopulmonary Aspergillosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Allergic bronchopulmonary aspergillosis; Asthma
  • Focus Adverse reactions; Proof of concept; Registrational
  • Sponsors Pulmatrix
  • Most Recent Events

    • 27 Jun 2024 This trial has been discontinued in France, according to European Clinical Trials Database record.
    • 28 Mar 2024 According to a Pulmatrix media release, On January 8, 2024, in agreement with its partner Cipla, Pulmatrix announced plans to stop patient enrollment at 8 subjects and company expects to complete all Phase 2b activities by the third quarter of 2024.
    • 22 Mar 2024 Status changed from active, no longer recruiting to discontinued.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top